- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Gary Lyman, MD, MPH: Challenges With Incorporating Biosimilars Into Cancer Care
Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes challenges with incorporating biosimilars into cancer care.
Transcript
I think the challenges, I look at them as 2 levels: one is for the provider and to some extent the patient, and that is skepticism. These are approved by a different process, different mechanism. We’re used to seeing these large phase 3 trials demonstrating efficacy and safety, and we're not seeing that with these, so there’s a skepticism, and many not wanting to be the first physician in their group to use a new agent when they've gotten very comfortable with the original biologics approved 20 years ago.
So I think there we need more education. [The American Society of Clinical Oncology, ASCO] has had a major effort that I had an opportunity to work with. We published some educational guidance in the Journal of Clinical Oncology 2 years ago. We’re putting on educational programs at the annual meeting, the same at the American Society of Hematology, and now here at [National Comprehensive Cancer Network, NCCN], so I think education about what a biosimilar is, what's the process, how it’s different, and why we should even rely on it, so that's very important
There's also some skepticism about how much of an impact on cost these agents will have and whether it really will bring down the incredibly high cost and rising cost of cancer care delivery in the United States.
It's not the whole solution, but I personally think it's a piece of the solution. We need other things at the policy level to rein in healthcare costs, but I think by biosimilar competition and reduced pricing can really help.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
